Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Estrogen and movement disorders.

K Kompoliti1

  • 1Department of Neurological Sciences, Rush-Presbyterian-St Luke's Medical Center, Rush University, Chicago, Illinois, USA.

Clinical Neuropharmacology
|January 8, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The importance of educational and psychological factors in Parkinson's disease quality of life.

European journal of neurology·2002
Same author

Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics.

Neurology·2002
Same author

Estrogen, progesterone, and tic severity in women with Gilles de la Tourette syndrome.

Neurology·2001
Same author

Rating scales and quantitative assessment of tics.

Advances in neurology·2001
Same author

Estrogen supplementation in the posthypoxic myoclonus rat model.

Clinical neuropharmacology·2001
Same author

Menstrual-related changes in motoric function in women with Parkinson's disease.

Neurology·2000
Same journal

Characterization of Propranolol Use and Outcomes in Traumatic Brain Injury at a Level I Trauma Center.

Clinical neuropharmacology·2026
Same journal

Review of Medications That Reduce Neurological Deficits in Patients With Traumatic Brain Injury.

Clinical neuropharmacology·2026
Same journal

Pre-Existing Peak-Dose Dyskinesia and Light Body Weight as Predictors of Ropinirole Patch Dose Modification in Parkinson Disease: A Multicenter Retrospective Study.

Clinical neuropharmacology·2026
Same journal

A Double-blind, Placebo-controlled Study of Lumateperone in the Treatment of Borderline Personality Disorder.

Clinical neuropharmacology·2026
Same journal

Yesterday Once More: Revisiting Catatonia in an Elderly Stroke Patient.

Clinical neuropharmacology·2026
Same journal

Overlapping Hyperosmolar Therapy in Patients With Elevated and Refractory Intracranial Pressure.

Clinical neuropharmacology·2026
See all related articles

Estrogen influences the brain's dopamine system, offering neuroprotection and affecting movement disorder symptoms. Understanding these effects can personalize treatments for women with movement disorders.

Area of Science:

  • Neurobiology
  • Endocrinology
  • Movement Disorders

Background:

  • Estrogen exerts biochemical and behavioral effects on the dopaminergic system.
  • These effects can be neuroprotective, modulating insults to dopamine pathways, or symptomatic, with documented suppressive and enhancing actions.
  • The mesostriatal dopaminergic system is a key target for estrogen's influence.

Purpose of the Study:

  • To review the neuroprotective and symptomatic effects of estrogen on the dopaminergic system.
  • To explore the role of estrogen in movement disorders such as Parkinson's disease, chorea, dystonia, tics, and myoclonus.
  • To inform therapeutic strategies for women with movement disorders and guide hormonal replacement therapy decisions.

Main Methods:

  • Review of preclinical literature on estrogen's effects on the dopaminergic system.

Related Experiment Videos

  • Analysis of studies investigating estrogen's influence on movement disorder prevalence, progression, and clinical signs.
  • Examination of estrogen's impact on medication efficacy in movement disorders.

    • Main Results:

    • Estrogen exhibits both neuroprotective and symptomatic modulatory effects on the dopaminergic system.
    • Evidence supports estrogen's influence on the occurrence, advancement, and clinical presentation of various movement disorders.
    • Estrogen impacts the effectiveness of medications used to treat movement disorders.

    Conclusions:

    • Understanding estrogen's modulation of the dopaminergic system is crucial for tailored therapies in women.
    • Estrogen's role necessitates consideration for optimizing treatments related to menstrual cycle fluctuations and postmenopausal hormonal replacement.
    • Further research can refine therapeutic approaches for women with movement disorders and genetic predispositions.